Patents by Inventor Mark Hurtt

Mark Hurtt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR DIAGNOSING AND MONITORING TREATMENT OF LEWY BODY DEMENTIA BY ASSESSING DOPAMINE TRANSPORTER LEVEL
    Publication number: 20160121003
    Abstract: A method of diagnosing Lewy Body Dementia in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where a lowered level of dopamine transporter in the patient is indicative of Lewy Body Dementia. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.
    Type: Application
    Filed: January 11, 2016
    Publication date: May 5, 2016
    Inventor: Mark Hurtt
  • Methods for imaging dopamine transporter level
    Patent number: 8084018
    Abstract: Presented is a method for assessing dopamine transporter levels in a selected area of a subject's central nervous system by SPECT imaging comprising administering an injection of a labeled dopamine transporter ligand at approximately the time the subject is positioned for SPECT imaging and initiating a SPECT acquisition for a duration of about 30 minutes commencing at about 15 minutes after administration of labeled dopamine transporter ligand; and assessing, based on said SPECT acquisition, the amount of labeled dopamine transporter ligand that is bound to dopamine transporter.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 27, 2011
    Assignee: Alseres Pharmaceuticals, Inc.
    Inventor: Mark Hurtt
  • METHODS FOR DIAGNOSING AND MONITORING TREATMENT OF LEWY BODY DEMENTIA BY ASSESSING DOPAMINE TRANSPORTER LEVEL
    Publication number: 20100312105
    Abstract: A method of diagnosing Lewy Body Dementia in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where a lowered level of dopamine transporter in the patient is indicative of Lewy Body Dementia. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.
    Type: Application
    Filed: October 29, 2008
    Publication date: December 9, 2010
    Applicant: ALSERES PHARMACEUTICALS, INC.
    Inventor: Mark Hurtt
  • METHODS FOR IMAGING DOPAMINE TRANSPORTER LEVEL
    Publication number: 20090110635
    Abstract: Presented is a method for assessing dopamine transporter levels in a selected area of a subject's central nervous system by SPECT imaging comprising administering an injection of a labeled dopamine transporter ligand at approximately the time the subject is positioned for SPECT imaging and initiating a SPECT acquisition for a duration of about 30 minutes commencing at about 15 minutes after administration of labeled dopamine transporter ligand; and assessing, based on said SPECT acquisition, the amount of labeled dopamine transporter ligand that is bound to dopamine transporter.
    Type: Application
    Filed: October 31, 2007
    Publication date: April 30, 2009
    Inventor: Mark Hurtt, JR.